51 results about "Large Intestine Cancer" patented technology

The present invention provides methods and materials related to the detection of colorectal neoplasm-specific markers (e.g., markers associated with colorectal cancer, markers associated with adenoma) in or associated with a subject's stool sample. In particular, the present invention provides methods and materials for identifying mammals (e.g., humans) having a colorectal neoplasm by detecting the presence and level of indicators of colorectal neoplasia such as, for example, long DNA (e.g., quantified by Alu PCR) and the presence and level of tumor-associated gene alterations (e.g., mutations in KRAS, APC, melanoma antigen gene, p53, BRAF, BAT26, PIK3CA) or epigenetic alterations (e.g., DNA methylation) (e.g., CpG methylation) (e.g., CpG methylation in coding or regulatory regions of bmp-3, bmp-4, SFRP2, vimentin, septin9, ALX4, EYA4, TFPI2, NDRG4, FOXE1) in DNA from a stool sample obtained from the mammal.

An object of the invention is to find a cancer-associated gene to be used as an index for detecting canceration of cells and degree of malignancy of cancer, so as to to provide a method for detecting cancer using the cancer-associated gene as an index and provide a method of suppressing / treating cancer using the cancer-associated gene as essential part. According to the present invention, specific genes which are amplified or deleted in large intestine cancer as compared with normal cell have been collectively found, and a method for detecting cancer using amplification or deletion of these cancer-associated genes as an index is provided. Further, cancer can be suppressed by introducing a gene which is deleted in cancer cells amond these cancer-associated genes into cancer and inhibiting the transcription product of the gene amplified.

An objective of the present invention is to obtain two types of substantively homogeneous cancer stem cell populations which can be characterized using the cell surface marker Lgr5, and to provide cancer therapeutics using an antibody against a cell membrane molecule specifically expressed in these cancer stem cells by identifying said cell membrane molecule. A further objective is to provide, using an antibody against a cell membrane molecule specifically expressed in cancer stem cells, a reagent for detecting cancer stem cells, and a method for diagnosing and sorting cancer patients. The present inventors discovered that highly pure large intestine cancer stem cells (CSC) can be obtained in a large quantity, and identified the two types of conditions of large intestine CSCs distinguishable through Lgr5 expression. Moreover, the present inventors discovered that an antibody against a cell membrane molecule specifically expressed in said cancer stem cells can damage said cells.

The invention discloses a preparing method of 23,24-dihydrocucurbitacin B and usage to treat tumor disease medicine, which comprises the following steps: using adverse current chromatogram; proceeding primary separation for acetic acid ethyl ester extract of trichosanthes anguina root; choosing two phase dissolvent system from light petroleum, chloroform and acetonitrile; merging and collecting the compound with cell toxic property; proceeding against phase high effective liquid phase color spectrum preparation with flowing phase as methanol and water gradient elution; collecting goal matter; volatilizing dissolvent; getting white crystalline powder; getting the product. This invention can be used to prepare the medicine of breast cancer, liver cancer and large intestine cancer, which possesses wide prospect.

A method of diagnosing colon cancer and / or colon polyp and a method of observing the postoperative course and monitoring the reoccurrence thereof characterized by comprising detecting cystatin SN protein by using anti-cystatin SN antibody. Thus, a kit for assaying cystatin SN conveniently applicable to the diagnosis to be performed before the barium examination and the endoscopic examination, which have been performed hitherto and impose burdens to patients, the indications for metastasis and reoccurrence and the evaluation of therapeutic effects. As a result, colon cancer and / or colon polyp can be diagnosed and monitored by a convenient method and a new therapeutic program can be quickly designed thereby.

The invention provides a method for establishing a colon cancer prognosis prediction model. The method comprises the following steps of: detecting the expression levels of SPARCL1 and P53 proteins in colon cancer tissues by immunohistochemistry; grading the tissue expression levels of the SPARCL1 and P53 proteins by a semi-quantitative method; and combining, analyzing and verifying the expression levels of the SPARCL1 and P53 proteins through a support vector machine, and finally establishing a judgment model. Immunohistochemistry detection, marker combination and support vector machine analysis are combined for establishing the colon cancer prediction model. The research shows that the model constructed by using the composition of the SPARCL1 and the P53 as a marker has experiment aid effect of predicting the prognosis of colon cancer patients. The model can be applied in postoperative transfer relapse risk prediction experiments of the colon cancer patients.

The invention provides a preparation method of a colon cancer cell strain expressed by stabilized silent PKM2 gene. The preparation method comprises the steps of constructing of shRNA lentiviral expression vector of human PKM2 gene, packaging and obtaining of lentivirus, DLD1 colon cancer lentivirus infecting, stabilized cell strain puromycin screening and Real-time PCR, Western blot identification. The experimental results show that the shRNA nucleotide sequence can be successfully inserted into the pLKO.1-puro expression vector, and the inhibitory effect on the expression of PKM2 gene is remarkable, endurable and stable. The prepared cell strain can be used as the experimental material for researching the regulating effect of PKM2 in malignant characteristics such as colon cancer cell energy metabolism, cell proliferation, cell migration and inflammation.

This invention relates to a method for detecting or inspecting colorectal cancer or esophageal cancer with high detection sensitivity and accuracy and with minimal invasiveness to a subject. Specifically, the invention relates to a method for inspecting cancer, the method involving: measuring, in vitro, the COTL1 protein in a body fluid sample taken from a subject; and, on the basis of the amount of said protein, evaluating whether or not the subject is affected by cancer. The invention also relates to a kit for diagnosing colorectal cancer or esophageal cancer, the kit comprising an antibody that can specifically bind to said protein, or a fragment of the antibody.

An objective of the present invention is to obtain two types of substantively homogeneous cancer stem cell populations which can be characterized using the cell surface marker Lgr5, and to provide cancer therapeutics using an antibody against a cell membrane molecule specifically expressed in these cancer stem cells by identifying said cell membrane molecule. A further objective of the present invention is to provide, using an antibody against a cell membrane molecule specifically expressed in cancer stem cells, a reagent for detecting cancer stem cells, and a method for diagnosing and sorting cancer patients. The present inventors discovered that highly pure large intestine cancer stem cells (CSC) can be obtained in a large quantity, and identified the two types of conditions of large intestine CSCs distinguishable through Lgr5 expression. Moreover, the present inventors discovered that an antibody against a cell membrane molecule specifically expressed in said cancer stem cells can damage said cells.

The invention provides fusobacterium nucleatum THCT14E2 which is obtained from large intestine cancer tumor tissue and does not belong to known fusobacterium nucleatum subsp.vincentii. The 16SrRNA gene sequence of the strain is as shown in SEQID NO:1. The classification designation of the THCT14E2 is Fusobacterium nucleatum, the preservation number is CCTCC NO:M 2019361, the preservation date is May 17th, 2019, and the preservation unit is China Center for Type Culture Collection. The colorectal cancer cell line and THCT14E2 co-culture result shows that the THCT14E2 can significantly promote colorectal cancer cell proliferation. Therefore, the THCT14E2 can promote understanding of micro-ecology diversity of rectum cancer, and facilitate function research of the fusobacterium nucleatum fromthe colorectal cancer.

The present invention relates to the detection of 15 mononucleotide polymorphism sites related with colorectal carcinoma and on 6 heterogenous substance metabolizing enzyme gene, the application of these mononucleotide polymorphism sites in predicting the liability of colorectal carcinoma, and the method of diagnosing and treating colorectal carcinoma. The present invention provides information favorable to preventing colorectal carcinoma as one main deadly disease and developing new effective therapy.

The invention discloses a probiotics oral liquid capable of maintaining beauty and keeping young and a production method thereof. The probiotics oral liquid takes Chinese wolfberry, red dates, longan,tartary buckwheat, polygonatum odoratum, radix angelicae, coix seeds, lily, lotus seeds and the like as raw materials which are medicinal and edible, the four raw materials of the red dates, the apricot kernels, the radix angelicae and the longan aril are warm in nature, and the four raw materials of the polygonatum odoratum, the coix seeds, the lily and the tartary buckwheat are cool in nature or cold in nature, the Chinese wolfberry fruits and the lotus seeds are mild in nature. and the raw material combination is mild in nature. The probiotics fermented oral liquid for maintaining beauty and keeping young is obtained by inoculating the raw materials with probiotics, performing primary solid fermentation, performing grinding to obtain pulp, performing sterilization, mixing the pulp withfruit juice, performing sterilization, inoculating probiotics, and performing secondary fermentation. The product is rich in soluble dietary fibers and oligosaccharide, contains a large amount of probiotics, has good effects of regulating intestines, relaxing bowels and removing toxins in bodies, and can achieve the medical values and health-care effects of reducing fat, losing weight, expellingtoxins, resisting oxidation, whitening skin, maintaining beauty, preventing and treating colorectal cancer and heart diseases after being eaten for a long time.

The invention relates to a tumor vaccine, in particular to a process for prreparing an autogenous colon cancer vaccine. The invention resolves the problem that in the prior art, autologous DC and colon tumor antigen of a patient are employed to prepare the autogenous colon cancer vaccine, which is unfavorable in killing effect. Steps include that the DC is externally induced and cultivated, obtaining the mature DC, the autogenous colon cancer vaccine is taken as the tumor antigen for preparing, the prepared tumor antigen and the prepared DC are mixed and cultivated by 24 hours, thereby obtaining the DC modified by the autogenous colon cancer vaccine, and the DC and lymphocyte are mixed and cultivated according to the quantitative proportion of 1 to 10-1000. The kill rate of the final obtained autogenous colon cancer vaccine to colon cancer cells is remarkedly increased.

Oligonucleotides directed against the survivin gene are provided for modulating the expression of survivin. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the survivin. Methods of using these compounds for modulation of survivin expression and for the treatment of diseases associated with either overexpression of survivin, expression of mutated survivin or both are provided. Examples of diseases are cancer such as lung, breast, colon, prostate, pancreas, lung, liver, thyroid, kidney, brain, testes, stomach, intestine, bowel, spinal cord, sinuses, bladder, urinary tract or ovaries cancers. The oligonucleotides may be composed of deoxyribonucleosides or a nucleic acid analogue such as for example locked nucleic acid or a combination thereof.

The invention discloses a noodle suitable for diabetes patients. The noodle is composed of the following raw materials in parts by weight: 40 to 50 parts of whole wheat, 30 to 40 parts of brown rice, 40 to 50 parts of cowpea, 30 to 40 parts of black soya bean, 20 to 25 parts of onion, 10 to 15 parts of green pepper, 20 to 25 parts of quail meat, 20 to 30 parts of mushroom, 20 to 30 parts of pumpkin, 1 to 2 parts of white clover herb, 1 to 2 parts of lithospermum, 1 to 3 parts of neocheiropteris palmatopedata stem, 1 to 2 parts of madder root, 1 to 2 parts of noodle additive and a proper amount of water. The preparation method takes whole wheat, brawn rice, cowpea, and black soya bean as the main materials; wherein the brown rice has a sweet taste and a warm character, and has the functions of fortifying the spleen, nourishing the stomach, tonifying the middle and qi, harmonizing the five internal organs, tranquilizing the nerve, and promoting the digestion and absorption; the cowpea has the functions of regulating the middle, tonifying qi, invigorating the stomach, tonifying the spleen, harmonizing the five internal organs, maintaining beauty, nourishing the body, generating energy, relieving diabetes, treating puke and diarrhea, and removing toxicity, moreover the phosphatide in the cowpea can promote the insulin secretion and joins the glycometabolism, so the cowpea is an ideal food for diabetes patients; the onion has the function of dissipating wind cold, promoting the secretion in the stomach, intestines and digestive tracts, promoting the digestion, reducing the blood pressure and the blood sugar, and preventing the thrombus formation, and has a certain refreshing function; the mushroom has the functions of preventing constipation, promoting toxicity discharge, preventing diabetes and colorectal cancer, and reducing cholesterol content.

The present invention provides one kind of molecular marker for the early stage detection and diagnosis of carcinoma of large intestine and gastric cancer, and the molecular marker is human neutrophil phylaxin HNP-1, -2, -3 protein. The process of detecting HNP-1, -2, -3 protein in tumor tissue includes high performance liquid chromatography (HPLC), SELDI-TOF-MS and immuno-histochemistry. The present invention has the advantages of high accuracy in early stage detection of carcinoma of large intestine and gastric cancer and lowered tumor detecting and diagnosing cost.

An application of polypeptide mark object in large intestine cancer detection includes knowing that correlation polypeptide content in serum specimen of large intestine cancer is obviously raised, using surface intensified laser de-absorption ionization flying time mass analyzer to determine correlation polypeptide content in serum specimen of patient for confirming whether detected patient is large intestine cancer patient or not.

The invention discloses a 1-(2,6-chlorphenyl)-3-substituted urea compound capable of acting on colon cancer, a preparation method and applications thereof. According to the present invention, the 1-(2, 6-dichlorophenyl)-3-(6-(substituted benzylamino)pyrimidine-4-yl) urea compound does not have toxic effect on the proliferation of BEAS-2B cells (normal lung cells), and has a certain inhibitory effect on three selected colon cancer cell lines including SW116 cells (human large intestine cancer cells), SW480 cells (human colon cancer cells) and SW620 cells (human colon cancer cells) so as to provide a certain antitumor activity.

A mass-sectrum model for detecting the serum protein of intestinal cancer, that is, non-intrusive detection of human intestinal cancer is composed of human serum protein mass-spectrum, mass spectrometer, and artificial nerve network analysis. Its configuration method includes preparing serum, collection of mass-spectrum data, and artificial nerve network analysis of mass-spectrum data. Its advantages are high sensitivity (more than 90%) and high specificity (more than 90%).

The invention relates to a formula and a preparation method of a Hui traditional Chinese medicine hedyotis diffusa willd anti-esophageal cancer oral liquid. According to the present invention, the Hui traditional Chinese medicine hedyotis diffusa willd anti-esophageal cancer oral liquid is the green high-tech Chinese herb for esophageal cancer treatment; and hedyotis diffusa willd, scutellaria barbata, panax notoginseng and other Chinese herbs are mixed according to a certain ratio, water is added, and decoction, extraction and concentration are performed to obtain the traditional Chinese medicine oral liquid; and the Hui traditional Chinese medicine hedyotis diffusa willd anti-esophageal cancer oral liquid mainly treats esophageal cancer, can further treat throat cancer, stomach cancer, large intestine cancer and other digestive system cancers, and has characteristics of moderate components and moderate doses, wherein the modern medical pharmacology experiment results prove that the selected medicines can treat cancers, and the body functions are fundamentally improved and the cell cancerization is prevented in the low cost manner so as to recover the health body.

The invention discloses cerasus humilis powder and a preparation method thereof. The cerasus humilis powder is prepared from 1-30 parts of cerasus humilis, 0-5 parts of Chinese wolfberry, 0-1 part oflutein, 0-1 part of taurine, 0-10 parts of honey, 0-10 parts of high fructose corn syrup, 0-1 part of granulated sugar powder, 0-1 part of stevioside and 0-3 parts of oligosaccharide; the preparationmethod comprises the steps of cleaning, denucleating, preheating, pulping and sterilizing the cerasus humilis, concentrating to obtain concentrated cerasus humilis juice, inoculating probiotics, and fermenting; and adding lutein, taurine and oligosaccharide, concentrating and drying to obtain the product. The cerasus humilis powder is rich in calcium, active probiotics, dietary fibers and oligosaccharide, has good effects of supplementing calcium, improving body immunity, regulating intestines, relaxing bowels and removing vivotoxin, and can achieve the medical values and health-care effects of reducing fat, losing weight, expelling toxin, beautifying skin, preventing and treating colorectal cancer and preventing and treating heart diseases after being eaten for a long time.

A traditional Chinese medicine prescription for treating large intestine cancer is disclosed. The prescription includes, by weight, 10 g of heterophylly falsestarwort root, 15 g of glehnia root, 10 g of largehead atractylodes rhizome, 20 g of poria, 10 g of processed pinellia tuber, 15 g of common aucklandia root, 10 g of dried orange peel, 20 g of common yam rhizome, 10 g of stir-fried hyacinth bean, 10 g of stir-fried inner membranes of chicken gizzards and 20 g of liquorice root. According to the preparing and using methods of the traditional Chinese medicine prescription, the traditional Chinese medicines are decocted with water, one dosage is taken a day, one treatment course includes 7 dosages, and 2-6 treatment courses are required.

The invention relates to monoclonal antibody CAb--1 heavy and light chain variable region gene of human carcinoma of large intestine, the encoded polypeptides by the said genes, and the use of the genes and the polypeptides in preparing the medicament for diagnosis or treatment of colon tumor or rectum tumor, wherein a set of designed expanded primers are introduced. Based on the gene, gene engineering method can be employed to construct and express small molecular genetic engineering antibody of various forms, such as Fab antibody, chimeric antibody, and antibody fusion protein, which can be used in preparing medicament for diagnosis or treatment of large intestine (colon, rectum) cancers.

The invention relates to traditional Chinese medicine for remedying alimentary tract tumor and a preparation method thereof. The traditional Chinese medicine is formed by refining 21 components of medicine such as tangerine peel, auckandia root, dandehon herb, angelica, cordate okuttuynia, hawthorn fruit, scutellaria root, phellodendron barkg, oldthread root, fresh ginger, syers woad leaf, chrysanthemum flower, mulberry bark, artemisia capillaries, fuligo plantae, honeysuckle flower, viola herb, Mikoudai, pulsatilla sinensis, Yeyuesha, and vinegar and so on, the medicine formula is rational, and has the function of tumor suppression, transfer resistance, recurrence prevention, and can adjust the immunity of human bodies to tumor patients, the cancer against capacity of human bodies is obviously improved, particularly, the effect of the medicine formula to oesophagus cancer, cardiac orifice cancer and large intestine cancer and so on is obvious, a clinical symptom can be relieved greatly, the pain of patients is reduced, the life quality is improved, the life period is prolonged, the gospel is brought along to wide tumor patients, and the invention has high social efficiency and economic efficiency.

The present invention discloses a biochip for assisting large intestine cancer targeted therapy. Meanwhile, the present invention further discloses a use method of the biochip and a preparation method for a bio-chip detection sample. According to the present invention, multiple gene loci can be simultaneously detected, such that the biochip of the present invention has characteristics of excellent performance and exact treatment effect prediction compared with the traditional single-detection K-RAS mutation chip, the large intestine cancer treatment remission rate of Erbitux can be increased to 41% from 36%, and the disease control rate can be increased to 82% from 76%; and due to use of immune microarray detection, advantages of short time consuming, high sensitivity, high accuracy, high throughput, and low cost of individual detection are provided.

The invention relates to monoclonal antibody CAb--2 heavy and light chain variable region gene of human carcinoma of large intestine, the encoded polypeptides by the said genes, and the use of the genes and the polypeptides in preparing the medicament for diagnosis or treatment of colon tumor or rectum tumor. By introducing a set of designed expanded primers, a strain of monoclonal antibody Cab-2 heavy and light chain variable region gene of human carcinoma of large intestine is cloned from the hybrid tumor cells. The gene can be applied in preparing the medicament for diagnosis or treatment of colon tumor or rectum tumor.

The present invention relates to a gene therapeutic agent using truncated soluble cDNA of VEGF receptor protein (VEGFR) and adeno-associated virus(AVV) system, and more particularly, relates to a gene therapeutic agent specific to large intestine cancer, bladder cancer and / or lung cancer, comprising a rAAV vector containing truncated soluble cDNA of VEGFR, and a rAAV vector containing the said vector and VEGF-A anti-sense cDNA. The gene therapeutic agent according to the present invention reduces the growth of tumors by inhibiting the expression and function of VEGF involved in angiogenesis necessary for the proliferation and metastasis of tumors. Thus, the inventive gene therapeutic agent can be effectively used to treat cancer at a gene level.

The invention is a kind of bupleurum root ext extracted from the southern bupleurum root and used to cure the hyperpiasia diseases and its method of extraction. The active components of the bupleurumroot ext at least includes the heterocyclic compound, with the Z or E position of the carbon 2(5), centered around the gamma- butyrolactone and the new bupleurum root lactone, isobupleurum root lactone, bupleurum root lactone similar and its ramification contained in the heterocyclic compound. From the results of the experiments of the drug toxicity, characteristics of the cell, animal experimentsand histologic section, we can know that the ext of the outhern bupleurum root can restrain the cancer cells of the liver cancer, lung cancer, oophoroma, large intestine cancer or swart brain glia cell tumour and specially kill the tomour cells with drug resistance to the taxales medicines after the chemotherapy. It can be a new resource of the drug screening of the tumor inhibitor.

The present invention discloses a detection method for predicting postoperation recurrence-free survival of colorectal cancers via gene expression states of two probes. The method includes: collecting cancerous tissue specimens excised in an operation of a colorectal cancer patient, extracting RNA samples, purifying the RNA samples, detecting the expressions of two specific probes, and calculating the number of a high expression probe to evaluate the patient's prognosis. The invention also discloses a probe set composed by the two probes, and a diagnostic kit containing the probe set. The detection method of the invention helps to improve the survival rate of the colorectal cancer patients. The risk degree of postoperative recurrence and metastasis occurrence of the patients can be quickly determined through the detection and the joint analysis of the two specific probes after that the colorectal cancer patients receive radical operations, so the detection method enables adjuvant treatments for the patients with a higher risk degree of recurrence to be done early to help prolong the survival time of the patients.

The present invention relates to a composition for diagnosis of liver metastasis of colorectal cancer and the use thereof, and more particularly to a composition for diagnosis of liver metastasis of colorectal cancer, which comprises either a substance for measuring the mRNA level of CCL7 (Chemokine (C-C motif) ligand 7) gene or a substance for measuring the level of a protein which is encoded by the gene. According to the present invention, whether liver metastasis of colorectal cancer occurred can be diagnosed by measuring the mRNA expression level of the CCL7 gene or the expression level of the CCL7 protein, and the use of the composition comprising an inhibitor of CCL7 gene allows the treatment of colorectal cancer or the liver metastasis of colorectal cancer.